Loading...
XSHE
002728
Market cap762mUSD
Oct 09, Last price  
10.24CNY
1D
3.02%
1Q
7.11%
Jan 2017
-46.56%
IPO
29.29%
Name

Teyi Pharmaceutical Group Co Ltd

Chart & performance

D1W1MN
XSHE:002728 chart
P/E
64.36
P/S
5.74
EPS
0.16
Div yield, %
0.50%
Shrs. gr., 5y
9.99%
Rev. gr., 5y
3.85%
Revenues
916m
+33.13%
202,139,105250,807,519305,131,322340,827,194342,720,954344,748,357516,540,038655,856,829686,943,602884,975,624921,122,275632,695,186758,160,497758,160,497886,570,9381,067,212,109687,785,166915,673,654
Net income
82m
+298.50%
24,099,88347,984,75169,694,93478,578,10780,554,68180,193,67781,105,34794,777,040106,342,798155,546,469171,710,43543,816,482126,917,422126,917,426178,204,109253,175,78920,495,00581,671,615
CFO
245m
P
22,315,50146,915,76069,806,575104,502,75074,229,58857,348,29668,867,455101,296,691102,956,107187,969,540221,644,491168,985,866256,814,750371,658,160198,557,705-22,549,753244,884,103
Dividend
Jun 18, 20260.15 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Teyi Pharmaceutical Group Co., Ltd. is a Chinese pharmaceutical company that focuses on the development, production, and sale of a broad range of medicinal products within China. Its offerings include both proprietary traditional Chinese medicines (TCMs) and various chemical products, such as finished preparations, raw materials, and other related chemical compounds. The company's portfolio of finished drugs targets several key therapeutic areas, including respiratory conditions (like cough and phlegm), kidney-related ailments, infectious diseases, cardiovascular issues, and digestive system disorders. Beyond finished medications, Teyi Pharmaceutical also supplies a variety of chemical raw materials and products; notable examples include aluminum magnesium carbonate, phenytoin, ferrous sulfate, glacial acetic acid, calcium chloride, sodium chloride, bismuth and citric acid series compounds, and zinc sulfate. Based in Taishan, China, the company underwent a name change in November 2016, transitioning from its previous identity as Guangdong Taicheng Pharmaceutical Co., Ltd. to its current name, Teyi Pharmaceutical Group Co., Ltd.

Key people

Danqing Xu
Chairman of the Board, General Manager · since 2018
Yanling Huang
Deputy General Manager · since 2015
Weicheng Wu
Deputy General Manager · since 2022
Songqing Xu
Vice Chairman of the Board, Deputy General Manager · since 2018
Rongjun Xu
Deputy General Manager · since 2025
Wenge Yan
Deputy General Manager · since 2024
Yongzhao Zhang
Deputy General Manager · since 2015
Ronghuang Xu
Executive Chairman of the Board, General Manager(Manager) · since 2025
Zilan Xu
Secretary of the Board · since 2025
Xiliang Chen
Chief Financial Officer, Secretary of the Board, Director · since 2018
Ruqing Yao
Staff Elected Director · since 2025
Hanqi Lai
Independent Director · since 2025
Independent Director · since 2015
Xiaobo Zhao
Independent Director · since 2025
IPO date
Jul 31, 2014
Employees
Domiciled in
CN
Incorporated in
CN
Headquarters & legal address
台山市台城长兴路9、11号
江门市, GD 510000
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT